Press Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Sista teckningsdag i Erbjudandet var den 13 september 2018. Genom Erbjudandet ökar antalet aktier från 8 203 566 till 15 353 566 under förutsättning...
Share issue in Asarina Pharma AB (publ) oversubscribed before listing on First North
2018-09-17 16:40
The subscription period in the Offer expired on 13 September, 2018. The Offer will increase the number of shares from 8,203,566 to 15,353,566 provided...
– Vi utvecklar världens första dedikerade behandling mot PMDS som är den allvarligaste formen av premenstruella besvär, säger...
Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm
2018-08-30 08:14
"We’re developing the world's first dedicated treatment for PMDD, the severest form of PMS," says Peter Nordkild, CEO of Asarina Pharma...
Asarina Pharma AB offentliggör prospekt i samband med nyemission om 142,8 MSEK inför notering på Nasdaq First North
2018-08-27 19:23
Asarina Pharma är ett svenskt forsknings- och utvecklingsbolag fokuserat på kroniska sjukdomar associerade med menstruationscykeln. Asarina...
Asarina Pharma AB publishes prospectus in connection with share issue of SEK 142,8M and listing on Nasdaq First North
2018-08-27 18:44
Asarina Pharma is a Swedish research and development company focused on chronic diseases associated with the menstrual cycle. Asarina Pharma is developing...
Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine
2018-07-09 11:16
“There are very few drugs out there for the worst type of PMS,” says new Asarina Pharma CMO Märta Segerdahl. “And the ones we have...
In spring Asarina Pharma launched the Phase IIB trials of Sepranolone, its first-in-class therapy for PMDD, the highly debilitating severest form of PMS...
Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
2018-04-27 08:53
The phase IIB study is recruiting 225-250 patients from Sweden, UK, Germany and Poland, to trial Sepranolone in PMDD. It’s an endogenous compound...
Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
2018-04-26 09:00
The phase IIB study is recruiting 225-250 patients from Sweden, UK, Germany and Poland, to trial Sepranolone in PMDD. It’s an endogenous compound...